Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Pathogenesis of optic-spinal MS].

Kazuo Fujihara1, Ichiro Nakashima, Tatsuro Misu

  • 1Department of Neurology, Tohoku University School of Medicine.

Rinsho Shinkeigaku = Clinical Neurology
|June 6, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DCIR-mediated inhibitory regulation of TLR7-MyD88 axis prevents autoimmune neuroinflammation.

iScience·2026
Same author

Headache prevalence and types in multiple sclerosis and related neuroimmunological diseases: A multicenter study.

Cephalalgia : an international journal of headache·2026
Same author

[Febrile infection-related epilepsy syndrome (FIRES) with the claustrum sign in a 55-year-old woman: a case report].

Rinsho shinkeigaku = Clinical neurology·2026
Same author

Outcomes and disease activity during and after pregnancy in Asian women with MOGAD.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Long-term effectiveness and safety of satralizumab for neuromyelitis optica spectrum disorder in a real-world clinical setting in Japan: A 2.5-year final analysis of a multicenter medical chart review (The SAkuraBeyond Study).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

A multicenter, retrospective study in patients with multiple sclerosis treated with natalizumab in a real-world setting in Japan: The REFIND study.

Multiple sclerosis and related disorders·2026

Optic-spinal multiple sclerosis (OSMS) shows a female predominance and lacks oligoclonal IgG bands (OB) in cerebrospinal fluid, distinguishing it from conventional MS (CMS). These findings suggest different underlying causes for OSMS.

Area of Science:

  • Neurology
  • Immunology
  • Neuroimmunology

Context:

  • Optic-spinal multiple sclerosis (OSMS), also known as relapsing neuromyelitis optica, is often debated as a distinct entity from conventional multiple sclerosis (CMS).
  • Diagnostic challenges arise from OSMS cases with minor central nervous system involvement or those that convert to CMS over time.
  • Understanding 'Pure OSMS,' defined by optic neuritis and myelitis with normal brain MRI, is crucial for accurate differentiation.

Purpose:

  • To delineate the distinct clinical and immunological characteristics of 'Pure OSMS' compared to CMS.
  • To investigate the immunological profile, including oligoclonal IgG bands (OB), cytokine levels, and T-cell subsets in the cerebrospinal fluid (CSF) of OSMS patients during relapses.
  • To explore potential differences in pathogenesis between OSMS and CMS based on these findings.

Related Experiment Videos

Summary:

  • Analysis of 'Pure OSMS' revealed a significant female preponderance and a consistent absence of oligoclonal IgG bands (OB) in CSF.
  • Immunological investigations showed negative OB, normal IL-10 and matrix metalloproteinase-9 levels in CSF during relapses, and a low proportion of CCR5+ Th1 cells compared to CMS.
  • Despite heterogeneity in clinical severity and HLA class II alleles, these findings suggest fundamental differences in the pathogenesis of OSMS and CMS.

Impact:

  • The distinct clinical and immunological profile of OSMS supports its classification as a separate entity from CMS.
  • These findings provide a basis for further research into the unique pathogenesis of OSMS.
  • Improved understanding can lead to more accurate diagnosis and potentially tailored therapeutic strategies for OSMS patients.